Protein Biosynthesis Interference in Disease

Protein Biosynthesis Interference in Disease offers a thorough discussion and overview of protein biosynthesis interference, its mechanisms of action, and influence over disease processes. This book examines the role of protein biosynthesis interference in Alzheimer’s and other neurodegenerative conditions, cancer and inflammatory disorders, with specific attention paid to the biochemical dynamics of tryptamine, biogenic amines and aminoacyl-tRNA synthetases in these pathologies. Methods of regulating protein translation and interference mechanisms, including gene therapy, are presented, empowering biochemists, molecular biologists, disease researchers, and health professionals to understand the underlying factors of protein disease and improve patient outcomes.

Enables biochemists, molecular biologists and disease researchers to advance disease prevention, laboratory testing, and treatment pathways for protein biosynthesis interference related disordersExamines the biochemical and molecular basis of protein biosynthesis interference in neurodegenerative disorders, cancer and inflammatory conditions, among other diseasesAnalyzes tryptamine, biogenic amines, and aminoacyl-tRNA synthetases dynamics in protein translation and possible treatment pathways regulating protein biosynthesis

1. Introduction 2. Tryptamine in the diet, human microbiome, tRNA aminoacylation-protein biosynthesis, host-microbiota metabolic interactions 3. Dimethyltryptamine, methyltryptamine, hallucinations and metals 4. Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT) and N, N-dimethyltryptamine (DMT): quantification methods 5. Tryptamine in renal pathologies and in pregnancy 6. Tryptophanyl-tRNA synthetase (TrpRS) inhibition or TrpRS gene (WARS) mutations and deletion result to TrpRS deficiency and pathologies 7. Tryptamine in liver diseases and alcohol abuse 8. Tryptamine and tyramine in tobacco smoking 9. Tryptamine and other biogenic amines in human vaginal samples 10. Tryptamine and tryptophan in human fecal samples: diet alters tryptamine levels 11. Tryptamine in human noncataractous and cataractous eye lenses 12. Tryptamine toxicity in rats, adrenalectomy, toxicity prevention 13. Microorganisms: the natural producers of tryptamine in food 14. Human gut bacterial sequence associated with Alzheimer’s disease and biogenic amines 15. Disease, factors and condition associated with Alzheimer’s disease (AD) and dementia support a concept that AD is a widespread systemic disorder 16. Arterial hypertension in comorbidity in dementia and Alzheimer’s disease, tryptamine in metabolic syndrome 17. Whole blood viscosity: biogenic amines, dementia and Alzheimer’s disease 18. Tryptamine and aminoacyl-tRNAs in sleep-wake and circadian disruptions 19. Senile plaques and/or neurofibrillary tangles in brain of non-demented individuals 20. Historical perspectives and future research directions 21. Tryptamine content and effects in humans and animals 22. Link protein half-lives to neurodegeneration: tryptamine treatment effects 23. Alzheimer’s disease human gut microbiome associated sequence (ADAS): predictive disease modeling with ADAS: generating ADAS variants from human samples 24. Tryptamine and other biogenic amines (BA) as modified and degradable factors 25. Tryptamine and TrpRS in cancer and other conditions 26. Experimental procedures: tryptophanyl-tRNA synthetase (TrpRS) characterization 27. Tryptophanyl-tRNA synthetase (TrpRS) in phosphosignaling 28. Tryptophanyl-tRNA synthetase antigenic epitopes and mimotpes 29. Interactomes: tryptophanyl-tRNA synthetase forms and other aminoacyl-tRNA synthetases 30. Tryptophanyl-tRNA synthetase in cell and organism survival 31. Tryptophanyl-tRNA synthetase sharing epitopes 32. Tryptamine and Tryptophanyl-tRNA synthetase in microvesicles, multivesicular bodies, and exosomes 33. Tryptophanyl-tRNA synthetase and tryptamine in protein kinase and cancer pathways 34. Global protein biosynthesis and aminoacyl-tRNA synthetase family